African Trypanosomiasis Market to Reach USD 137.8 Million by 2031 | CAGR 5.3%

News Apr 6, 2026 0 5 Add to Favourites

According to a newly published market research report by 24LifeSciences, global African Trypanosomiasis market was valued at USD 92.4 million in 2024 and is projected to reach USD 137.8 million by 2031, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period 2025-2031.

African Trypanosomiasis, clinically known as sleeping sickness, is a vector-borne parasitic disease caused by protozoan parasites of the genus Trypanosoma. The disease manifests in two primary variants: Trypanosoma brucei rhodesiense (East African) and Trypanosoma brucei gambiense (West African). While historically prevalent in 36 sub-Saharan countries, recent WHO control efforts have significantly reduced case numbers. The market remains vital for developing diagnostics and treatments in endemic regions.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15547/african-trypanosomiasis-market

Endemic Disease Burden Drives Market Growth

The persistent presence of African Trypanosomiasis in sub-Saharan Africa continues to fuel market demand, with approximately 65 million people at risk of infection annually. The disease remains endemic in 36 countries, though reported cases have declined to an estimated 1,500-2,000 yearly due to successful control programs. However, underreporting remains a significant concern, particularly in remote areas where healthcare access is limited.

The market's steady growth reflects ongoing investments from global health organizations and national governments. The African Union's continental elimination program aims to interrupt transmission of gambiense HAT by 2030, creating structured demand for improved diagnostics and therapies.

Technological Advancements in Diagnostics and Treatment

Recent years have seen notable progress in diagnostic technologies, with rapid test kits now detecting parasite antigens in 15 minutes - a significant improvement over traditional microscopy methods. New PCR-based diagnostics show 98% sensitivity in field trials, though cost remains a barrier to widespread adoption at $50-75 per test.

In therapeutics, the introduction of fexinidazole - the first all-oral treatment for both stages of gambiense sleeping sickness - has transformed treatment paradigms. Twelve compounds are currently in clinical development pipeline, including novel benzoxaboroles showing 89% cure rates in phase II trials.

Market Challenges: Complex Treatment Landscape and Access Barriers

Despite positive developments, the market faces substantial obstacles:

High treatment costs averaging $300-500 per course in resource-limited settings
Complex drug administration protocols requiring hospitalization for most existing therapies
Emerging drug resistance in some endemic regions threatening treatment efficacy
Distribution challenges in rural areas where 70% of cases occur

Additionally, the niche nature of this neglected tropical disease limits commercial incentives for large-scale pharmaceutical investment.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/african-trypanosomiasis-market-15547

Sub-Saharan Africa Dominates Market Geography

The sub-Saharan African region accounts for over 90% of the global market due to disease endemicity, with particularly high concentration in:

Democratic Republic of Congo (leading case burden)
Central African Republic
South Sudan
Uganda
Guinea

East Africa shows higher prevalence of the acute Rhodesiense form, while West Africa experiences more chronic Gambiense infections. Surprisingly, North America accounts for 18% of diagnostic revenue due to testing requirements for returned travelers and military personnel.

Hospitals and Clinics Lead End-User Segments

By application, hospitals and clinics represent the largest treatment settings due to the specialized care requirements of advanced cases.
Diagnostically, blood sample testing maintains 62% market share for early-stage detection, while cerebrospinal fluid analysis remains critical for neurological stage confirmation.

Competitive Landscape: Specialization and Collaboration

The market features a mix of multinational pharmaceutical companies and focused biotech firms, with Sanofi and Genzyme jointly holding 42% therapeutic share. The competitive environment emphasizes:

Public-private partnerships for drug development
Collaboration with endemic country research institutions
Innovation in point-of-care diagnostics

Key companies profiled in the report include:

Sanofi
Genzyme Corporation
aRigen Pharmaceuticals
Immtech Pharmaceuticals
Anacor Pharmaceuticals
Drugs for Neglected Diseases initiative (DNDi)
WHO Tropical Disease Research
and More

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/african-trypanosomiasis-market-15547

Market Opportunities: New Formulations and Disease Elimination

Significant growth potential exists in oral drug formulations that could transform treatment accessibility in remote areas. The development pipeline includes several promising candidates that may reach market within 5 years. Furthermore, point-of-care diagnostic innovations present a $120 million opportunity by 2027, particularly for tests combining high accuracy with low infrastructure requirements.

The push for disease elimination by 2030 creates structured demand for both surveillance tools and curative treatments. Success would transition the market toward prevention and outbreak response rather than chronic disease management.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15547/african-trypanosomiasis-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/african-trypanosomiasis-market-15547

About 24LifeSciences

24LifeSciencesis a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.